Clinical Performance and Safety of Suture-TOOL

January 14, 2023 updated by: Suturion AB

Clinical Performance and Safety of Suture-TOOL for Abdominal Wound Closure in Men and Women Patients Undergoing Elective Open Abdominal Surgery

The goal of this single arm intervention study is to investigate the safety and performance of a suturing device for closure of the midline incision after open abdominal surgery. The study population consists of 38 patients selected for open abdominal procedures for malignant and benign colorectal disease.

The main question it aims to answer is:

• If the device facilitates a Suture-Length to Wound-Length (SL/WL) ratio of 4:1

Participants laparotomy wound will be closed with the device at the end of the operation and closure related data as closure time and SL/WL ratio will be calculated. The wound will be assessed for infection during the postoperative stay and the chart will be reviewed for wound dehiscence and wound infection.

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

38

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Informed consent: signed written informed consent before inclusion in the investigation
  2. Sex, age: male and female patients, ≥ 18 years old
  3. Surgery: elective open abdominal surgery for benign or malignant colorectal disease through midline incision.

    Anticipated incision length ≥ 12 cm

  4. Body Mass Index (BMI): 18 - 40 kg/m2 inclusive
  5. Full comprehension: ability to comprehend the full nature and purpose of the investigation, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire investigation.

Exclusion Criteria:

  1. Abdominal Surgery: previous abdominal surgery involving the midline
  2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the investigation according to the Investigator's opinion; existing midline hernia, cutaneous infection, fistula, psoriasis of abdominal skin; morbidly obese patients
  3. Pre-operative findings: any pre-operative findings identified by the surgeon/Investigator that may preclude the conduct of the investigation procedures
  4. Allergy: history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers could affect the outcome of the investigation
  5. Diseases: known or identified at surgery disseminated cancer disease; collagen diseases and immune deficiency disorders, according to the Investigator's opinion. Significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that according to the Investigator's opinion may interfere with the aim of the investigation
  6. Life expectancy: life expectancy less than 1 year
  7. Medications: any medication that could interfere with the investigation procedures or investigation outcome, according to the Investigator's opinion. Hormonal contraceptives for women are allowed
  8. Pregnancy and lactation: positive pregnancy test at screening (if applicable); pregnant or breastfeeding women
  9. Vulnerable subjects: Individuals unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced because of a compromised position, expectation of benefits or fear of retaliatory response (ISO 14155:2020 §3.55) will be excluded

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Single arm
Closure of the abdomen after laparotomy with Suture-TOOL.
Suture device for fast and standardized closure of the abdominal fascia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients with Suture length/Wound length (SL/WL) ratio ≥ 4
Time Frame: Measured during laparotomy closure.
SL/WL-ratio of patients laparotomy closures will be calculated by measuring (centimeter) and dividing the length of used suture with the length of the laparotomy wound.
Measured during laparotomy closure.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stitch count
Time Frame: Measured during laparotomy closure
Number of stitches used for laparotomy closure
Measured during laparotomy closure
Numbers of sutures used
Time Frame: Counted during laparotomy closure
Counted during laparotomy closure
Incision closure time
Time Frame: Measured during laparotomy closure
Time (seconds) from first to last knot during laparotomy closure
Measured during laparotomy closure
Surgeons´ comfort with device during closure
Time Frame: After laparotomy closure
VAS assessment
After laparotomy closure
Surgeons´ satisfaction with final closure result
Time Frame: After laparotomy closure
VAS assessment
After laparotomy closure

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incision not following the midline (exposure of rectus muscle)
Time Frame: During the whole study period of up to 8 months
Assessment of midline incision
During the whole study period of up to 8 months
Thickness of subcutaneous fat
Time Frame: During the whole study period of up to 8 months
Measurement of subcutaneous fat (millimeter)
During the whole study period of up to 8 months
Glove punctures
Time Frame: During the whole study period of up to 8 months
Standardized assessment of puncture holes
During the whole study period of up to 8 months
Re-operation(s) number
Time Frame: 45 days after surgery
Chart review
45 days after surgery
Reasons for unscheduled post-surgery visits
Time Frame: 45 days after surgery
Chart review
45 days after surgery
Type of adverse effects
Time Frame: During the whole study period of up to 8 months
All adverse effects derived by spontaneous, unsolicited reports of the subjects or users/handlers, by observation and by routine open questioning will be collected and reported.
During the whole study period of up to 8 months
Type of adverse device effects
Time Frame: During the whole study period of up to 8 months
Identification of adverse device effects
During the whole study period of up to 8 months
Type of device deficiencies
Time Frame: During the whole study period of up to 8 months
Identification of device deficiences
During the whole study period of up to 8 months
Reasons for device replacement during surgery
Time Frame: During the whole study period of up to 8 months
Identification during study period
During the whole study period of up to 8 months
Patients with wound infections
Time Frame: 45 days after surgery
Wound infection postoperatively
45 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Marcus Edelhamre, MD Phd, Region Skane

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2023

Primary Completion (Anticipated)

August 30, 2023

Study Completion (Anticipated)

August 30, 2023

Study Registration Dates

First Submitted

January 9, 2023

First Submitted That Met QC Criteria

January 14, 2023

First Posted (Actual)

January 23, 2023

Study Record Updates

Last Update Posted (Actual)

January 23, 2023

Last Update Submitted That Met QC Criteria

January 14, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • CRO-21-149
  • CIV-22-09-040607 (Other Identifier: Swedish Medical Products Agency)
  • SUT 001 (Other Identifier: Suturion AB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Wound Infection

Clinical Trials on Suture-TOOL

3
Subscribe